Richard L. Lindstrom net worth and biography

Richard Lindstrom Biography and Net Worth

Director of Ocular Therapeutix

Richard Lindstrom, M.D., has served on the Board of Directors since 2012. Dr. Lindstrom is a founder and Attending Surgeon at Minnesota Eye Consultants, P.A., a provider of eye care services. A Board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery, Dr. Lindstrom has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally. He is Adjunct Clinical Professor Emeritus: University of Minnesota, Department of Ophthalmology. He is Board Member: University of Minnesota Foundation, Visiting Professor, UC Irvine: Gavin Herbert Eye Institute. He also is past President of the American Society of Cataract and Refractive Surgeons and the International Society of Refractive Surgery. Dr. Lindstrom holds a B.A. degree in pre-medical studies, a B.S. degree in Medicine and an M.D. degree from the University of Minnesota.

What is Richard L. Lindstrom's net worth?: The estimated net worth of Richard L. Lindstrom is at least $164,430.00 as of September 30th, 2022. Dr. Lindstrom owns 26,100 shares of Ocular Therapeutix stock worth more than $164,430 as of April 8th. This net worth evaluation does not reflect any other investments that Dr. Lindstrom may own. Learn More about Richard L. Lindstrom's net worth.
How do I contact Richard L. Lindstrom?: The corporate mailing address for Dr. Lindstrom and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at chris.brinzey@westwicke.com. Learn More on Richard L. Lindstrom's contact information.
Has Richard L. Lindstrom been buying or selling shares of Ocular Therapeutix?: Richard L. Lindstrom has not been actively trading shares of Ocular Therapeutix during the last quarter. Most recently, Richard L. Md Lindstrom sold 10,000 shares of the business's stock in a transaction on Thursday, May 20th. The shares were sold at an average price of $14.30, for a transaction totalling $143,000.00. Following the completion of the sale, the director now directly owns 90,000 shares of the company's stock, valued at $1,287,000. Learn More on Richard L. Lindstrom's trading history.
Who are Ocular Therapeutix's active insiders?: Ocular Therapeutix's insider roster includes Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.
Are insiders buying or selling shares of Ocular Therapeutix?: During the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 45,949 shares worth more than $340,138.76. The most recent insider tranaction occured on February, 24th when insider Pravin Dugel sold 21,475 shares worth more than $147,533.25. Insiders at Ocular Therapeutix own 3.5% of the company. Learn More about insider trades at Ocular Therapeutix.
Information on this page was last updated on 2/24/2025.

Richard L. Lindstrom Insider Trading History at Ocular Therapeutix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/20/2021	Sell	10,000	$14.30	$143,000.00	90,000
3/13/2019	Buy	56,441	$4.33	$244,389.53	100,000

Richard L. Lindstrom Buying and Selling Activity at Ocular Therapeutix

Ocular Therapeutix Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $6.30

$5.85

$6.61

50 Day Range

MA: $7.39

$5.93

$8.51

2 Week Range

Now: $6.30

$4.06

$11.78

Volume

2,331,457 shs

Average Volume

1,557,651 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49